When stratifying patients in BRAF V600E and non-V600E subgroups, we demonstrated that BRAF V600E mutant NSCLC treated with first-line chemotherapy displayed a significantly prolonged OS compared to those receiving single-agent immunotherapy (Median OS = 20.4 vs. 7.0 mos. This evidence concerns the gene BRAF and non-small cell lung carcinoma.